Showing 201 - 220 results of 870 for search '"prostate"', query time: 0.07s Refine Results
  1. 201

    Primary Sarcoma of the Specialised Prostatic Stroma: A Case Report and Review of the Literature by Rosanna Zamparese, Francesco Corini, Antonio Braccischi, Antonella D'Angelo, Lucilla Diamanti, Marina Del Vecchio, Willy Giannubilo, Vladimiro Mambelli

    Published 2011-01-01
    “…Primary sarcoma tumours of the prostate are rare and are classified, according to their histology, as stromal tumours of uncertain malignant potential (STUMP) and stromal prostatic sarcoma (PS; low and high grade). …”
    Get full text
    Article
  2. 202
  3. 203

    Characterizing ProstivaTM RF Treatments of the Prostate for BPH with Gadolinium-Enhanced MRI by Christian Huidobro, Benjamin Larson, Samuel Mynderse, James J. Myers, David Busel, Cristian Acevedo, Thayne R. Larson, Lance A. Mynderse

    Published 2009-01-01
    “…Transurethral needle ablation (TUNA) is an accepted and effective therapy for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). ProstivaTM (Medtronic, Shoreview, MN) is the newest-generation device, which includes a new needle design and radio frequency (RF) generator. …”
    Get full text
    Article
  4. 204
  5. 205
  6. 206

    Inverse Relationship Between Leydig Cell Density and Metastatic Potential of Prostatic Adenocarcinoma by W. John Wang, Y. Albert Yeh, Paul Stout, Kang Fan

    Published 1999-01-01
    “…Purpose: Evaluate the relationship between metastatic potential of prostatic adenocarcinoma (PC) and testicular Leydig cell density. …”
    Get full text
    Article
  7. 207
  8. 208

    Mitochondrial Cytochrome c Oxidase Subunit 1 Sequence Variation in Prostate Cancer by Takara A. Scott, Rebecca S. Arnold, John A. Petros

    Published 2012-01-01
    “…Mitochondrial DNA (mtDNA) mutations have been described in every adult neoplasm including prostate cancer. There are marked racial differences in mutations within the cytochrome c oxidase subunit 1 (COI) gene in individuals with prostate cancer (PCa). …”
    Get full text
    Article
  9. 209

    Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies by Tilman Todenhöfer, Arnulf Stenzl, Lorenz C. Hofbauer, Tilman D. Rachner

    Published 2015-01-01
    “…Maintaining bone health remains a clinical challenge in patients with prostate cancer (PC) who are at risk of developing metastatic bone disease and increased bone loss due to hormone ablation therapy. …”
    Get full text
    Article
  10. 210

    Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma by Osama Diab, Dan Mcentire, Thamer Kassim, Ali Nayfeh, Abdel Rahman Dajani, Mitchell Kerfeld, Jonathon Campbell, Adbullah Alsuwaidan, Mahmoud Abu Hazeem, Maryam Gbadamosi-Akindele

    Published 2019-01-01
    “…We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. …”
    Get full text
    Article
  11. 211

    It Suddenly Occurred: Extensive Subcutaneous Emphysema after Bipolar Transurethral Resection of Prostate by Murat Bagcioglu, Mert Ali Karadag, Ramazan Kocaaslan, Cafer Mutlu Sarikas, Mustafa Gok, Omer Erkam Arslan

    Published 2015-01-01
    “…We report the first case of a wide subcutaneous emphysema due to microperforations of prostatic capsule, without a bladder perforation after TURP. …”
    Get full text
    Article
  12. 212
  13. 213

    A Perspective on Withania somnifera Modulating Antitumor Immunity in Targeting Prostate Cancer by Seema Dubey, Manohar Singh, Ariel Nelson, Dev Karan

    Published 2021-01-01
    “…This article signifies the cumulative information about the role of WFA in modulating antitumor immunity and its potential in targeting prostate cancer.…”
    Get full text
    Article
  14. 214
  15. 215

    Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer by Manish Kohli, Rui Qin, Rafael Jimenez, Scott M. Dehm

    Published 2012-01-01
    “…Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). …”
    Get full text
    Article
  16. 216
  17. 217

    Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix by Shawn Y. Ong, Josephine Taverna, Clint Jokerst, Thomas Enzler, Emad Hammode, Elisa Rogowitz, Myke R. Green, Hani M. Babiker

    Published 2015-01-01
    “…Disseminated intravascular coagulation (DIC) with excessive fibrinolysis (XFL) is a rare and acute life-threatening variant of DIC in patients with prostate cancer. Patients present with coagulopathy, hypofibrinogenemia, and systemic bleeding. …”
    Get full text
    Article
  18. 218
  19. 219
  20. 220